These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

952 related articles for article (PubMed ID: 32527802)

  • 1. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.
    Premkumar L; Segovia-Chumbez B; Jadi R; Martinez DR; Raut R; Markmann A; Cornaby C; Bartelt L; Weiss S; Park Y; Edwards CE; Weimer E; Scherer EM; Rouphael N; Edupuganti S; Weiskopf D; Tse LV; Hou YJ; Margolis D; Sette A; Collins MH; Schmitz J; Baric RS; de Silva AM
    Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32527802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus Antibodies.
    Premkumar L; Segovia-Chumbez B; Jadi R; Martinez DR; Raut R; Markmann A; Cornaby C; Bartelt L; Weiss S; Park Y; Edwards CE; Weimer E; Scherer EM; Roupael N; Edupuganti S; Weiskopf D; Tse LV; Hou YJ; Margolis D; Sette A; Collins MH; Schmitz J; Baric RS; de Silva AM
    medRxiv; 2020 May; ():. PubMed ID: 32511572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
    Piccoli L; Park YJ; Tortorici MA; Czudnochowski N; Walls AC; Beltramello M; Silacci-Fregni C; Pinto D; Rosen LE; Bowen JE; Acton OJ; Jaconi S; Guarino B; Minola A; Zatta F; Sprugasci N; Bassi J; Peter A; De Marco A; Nix JC; Mele F; Jovic S; Rodriguez BF; Gupta SV; Jin F; Piumatti G; Lo Presti G; Pellanda AF; Biggiogero M; Tarkowski M; Pizzuto MS; Cameroni E; Havenar-Daughton C; Smithey M; Hong D; Lepori V; Albanese E; Ceschi A; Bernasconi E; Elzi L; Ferrari P; Garzoni C; Riva A; Snell G; Sallusto F; Fink K; Virgin HW; Lanzavecchia A; Corti D; Veesler D
    Cell; 2020 Nov; 183(4):1024-1042.e21. PubMed ID: 32991844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
    Tai W; Zhang X; He Y; Jiang S; Du L
    Antiviral Res; 2020 Jul; 179():104820. PubMed ID: 32405117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
    Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Lorenzi JCC; Finkin S; Hägglöf T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ
    Cell; 2020 Aug; 182(4):828-842.e16. PubMed ID: 32645326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological differentiation between COVID-19 and SARS infections.
    Chia WN; Tan CW; Foo R; Kang AEZ; Peng Y; Sivalingam V; Tiu C; Ong XM; Zhu F; Young BE; Chen MI; Tan YJ; Lye DC; Anderson DE; Wang LF
    Emerg Microbes Infect; 2020 Dec; 9(1):1497-1505. PubMed ID: 32529906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.
    Iyer AS; Jones FK; Nodoushani A; Kelly M; Becker M; Slater D; Mills R; Teng E; Kamruzzaman M; Garcia-Beltran WF; Astudillo M; Yang D; Miller TE; Oliver E; Fischinger S; Atyeo C; Iafrate AJ; Calderwood SB; Lauer SA; Yu J; Li Z; Feldman J; Hauser BM; Caradonna TM; Branda JA; Turbett SE; LaRocque RC; Mellon G; Barouch DH; Schmidt AG; Azman AS; Alter G; Ryan ET; Harris JB; Charles RC
    Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33033172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
    McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
    Dai L; Zheng T; Xu K; Han Y; Xu L; Huang E; An Y; Cheng Y; Li S; Liu M; Yang M; Li Y; Cheng H; Yuan Y; Zhang W; Ke C; Wong G; Qi J; Qin C; Yan J; Gao GF
    Cell; 2020 Aug; 182(3):722-733.e11. PubMed ID: 32645327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.
    Yu F; Xiang R; Deng X; Wang L; Yu Z; Tian S; Liang R; Li Y; Ying T; Jiang S
    Signal Transduct Target Ther; 2020 Sep; 5(1):212. PubMed ID: 32963228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.
    Ripperger TJ; Uhrlaub JL; Watanabe M; Wong R; Castaneda Y; Pizzato HA; Thompson MR; Bradshaw C; Weinkauf CC; Bime C; Erickson HL; Knox K; Bixby B; Parthasarathy S; Chaudhary S; Natt B; Cristan E; El Aini T; Rischard F; Campion J; Chopra M; Insel M; Sam A; Knepler JL; Capaldi AP; Spier CM; Dake MD; Edwards T; Kaplan ME; Scott SJ; Hypes C; Mosier J; Harris DT; LaFleur BJ; Sprissler R; Nikolich-Žugich J; Bhattacharya D
    Immunity; 2020 Nov; 53(5):925-933.e4. PubMed ID: 33129373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses.
    Yang Y; Li F; Du L
    J Nanobiotechnology; 2024 May; 22(1):304. PubMed ID: 38822339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
    Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
    Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients.
    Walker SN; Chokkalingam N; Reuschel EL; Purwar M; Xu Z; Gary EN; Kim KY; Helble M; Schultheis K; Walters J; Ramos S; Muthumani K; Smith TRF; Broderick KE; Tebas P; Patel A; Weiner DB; Kulp DW
    J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32855181
    [No Abstract]   [Full Text] [Related]  

  • 20. Potently neutralizing and protective human antibodies against SARS-CoV-2.
    Zost SJ; Gilchuk P; Case JB; Binshtein E; Chen RE; Nkolola JP; Schäfer A; Reidy JX; Trivette A; Nargi RS; Sutton RE; Suryadevara N; Martinez DR; Williamson LE; Chen EC; Jones T; Day S; Myers L; Hassan AO; Kafai NM; Winkler ES; Fox JM; Shrihari S; Mueller BK; Meiler J; Chandrashekar A; Mercado NB; Steinhardt JJ; Ren K; Loo YM; Kallewaard NL; McCune BT; Keeler SP; Holtzman MJ; Barouch DH; Gralinski LE; Baric RS; Thackray LB; Diamond MS; Carnahan RH; Crowe JE
    Nature; 2020 Aug; 584(7821):443-449. PubMed ID: 32668443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.